UCB at J.P. Morgan European Healthcare CEO Call Series: growth push

UCB outlined a decade-long growth strategy centered on BIMZELX, which has treated about 150,000 patients and achieved 80% marketplace access across major indications. Management expects expanding access and volume growth to offset lower net pricing from rebates, while BIMZELX continues to gain share in psoriasis and hidradenitis suppurativa. Four acquisitions, including Neurona and Candid Therapeutics, broaden the late-decade pipeline, while PPP Phase III top-line data are expected in 2028 and galvokimig Phase IIb enrollment finished ahead of schedule.

Analysis

The investable issue is not whether BIMZELX is clinically differentiated, but whether incremental U.S. formulary access produces enough new starts to outrun the immediate rebate reset. This creates a likely quarterly trough in net price/mix before volume conversion becomes visible, making near-term consensus revenue estimates vulnerable even if prescription trends remain healthy. UCB’s valuation discount is therefore unlikely to close on management rhetoric alone; it needs evidence in reported U.S. net sales, new-to-brand share, and confirmation that gross-to-net deterioration is moderating by the 2027 contracting cycle.

Competitive effects are asymmetric. Broader HS awareness and additional entrants can expand the treated population, but AbbVie’s HUMIRA/SKYRIZI franchise and Novartis’ COSENTYX retain payer leverage and field-scale advantages; UCB must pay for preferred placement to overcome that distribution moat. The most underappreciated risk is that the company’s acquisition-led pipeline broadening raises R&D and integration costs just as BIMZELX price realization is declining, limiting operating leverage and turning a seemingly inexpensive earnings multiple into a value trap.

Over 6-18 months, HS diagnosis expansion is the most credible upside to current forecasts because it can enlarge the addressable pool rather than merely take share. In contrast, galvokimig, Neurona and cizutamig should receive limited valuation credit until subcutaneous dose translation, registrational design, and reproducible efficacy are externally demonstrated; management’s early signals are not yet sufficient to underwrite late-decade cash flows. Contrarian view: the market may be too focused on class efficacy comparisons and too little on payer economics—superior outcomes do not guarantee premium net pricing in a crowded immunology market.

Key Decisions for Investors

• Maintain a watch-list long in UCB rather than chase the call-driven move; initiate only after the next results show U.S. BIMZELX sales growth accelerating despite lower net price, with new-to-brand share stable or rising. Target a 12-month rerating toward European specialty-pharma peers if revenue durability is validated; exit if management cuts EBIT guidance or reports two consecutive quarters of declining U.S. net sales.
• For a relative-value expression over the next 3-6 months, consider long UCB versus short NVS only if UCB trades at a material valuation discount while BIMZELX prescription data inflect upward. The thesis captures UCB-specific access conversion while hedging broad immunology and European pharma beta; stop out if COSENTYX gains payer preference or UCB’s gross-to-net pressure exceeds guidance.
• Do not assign material portfolio value to Neurona or cizutamig before regulatory clarity. Set alerts for Neurona Phase III protocol initiation and any FDA designation, and for cizutamig’s indication-specific Phase I dataset; either could justify incremental upside, while study-design delays would expose the acquisition pipeline as a capital-allocation drag.
• Monitor 2027 PBM contracting outcomes as the key 1-3 month estimate-risk catalyst: improved first-line coverage without a disproportionate rebate step-up supports adding exposure; broader access accompanied by weak net-price guidance is a reason to defer.